Our findings showed that rs546950 polymorphism of PRKCI decreased the risk of PCa in codominant (OR=0.35, 95%CI=0.19-0.64, P<0.001, CT vs CC) and dominant (OR=0.39, 95%CI=0.22-0.69, P=0.001, CT+TT vs CC) inheritance model tested.
In conclusion, we found an association with prostate cancer risk for two SNPs belonging to PRKCI, a gene which is frequently overexpressed in various neoplasms, including prostate cancer.